Investor Relations

SynBiotic SE

Investor Relations

Welcome to the Investor Relations Portal of SynBiotic SE, one of the leading German providers of cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.

About the Stock

  • Basic Information
  • Stock Chart
  • Shareholder Structure
  • Analysts

WKN: A2LQ77

ISIN: DE000A2LQ777

Ticker Symbol: SBX

Stock Exchange: Xetra, Düsseldorf, Tradegate, GETTEX

Total number of shares: 2.625.000

Share capital: 2.625.000,00 EUR 

Analyst                                          Recommendation          Target Price    Last Research

Hauck & Aufhäuser                         BUY                                   75 EUR              May2021

Edison Investment Research         RELEASE AUGUST 2021

Alster Research                                RELEASE JULI 2021

Baader Bank                                    RELEASE JULI 2021

Stifel                                                   RELEASE AUGUST 2021



About the Company

  • Vision
  • Organs
  • Analyst Persentation

 

Vision:                 Europe's #1 ecosystem for solutions based on
                             cannabinoids and terpenes

Mission:               We are building Europe's largest ecosystem for cannabinoid & terpene                               
                             based solutions and transform ideas into better brands &                                           
                             Products for multi-billion markets like pain, sleep & anxiety.

Growth:               We grow 75% year on year (20% organic, 55% inorganic).

Strategy:             We cover the entire cannabinoid value chain with our buy & build strategy and
                              consolidate the strongest players in the industry under one roof. SynBiotic SE is divided into the
                              following verticals:

                              1) D2C & medical brands  
                              2) Production & Biotech
                              3) Research & Development 

SynBiotic with the legal form SE (European Company or Societas Europaea) has a monistic management model ("one-tier system"). In the monistic system, the management is not institutionally separated from the supervision. Rather, these two functions are performed by one and the same body (board of directors, administrative board).

 

Executive Director

LARS MÜLLER

Serial entrepreneur with over 10 years of experience in scaling profitable businesses. Deep industry expertise from seed to shelf, genetics, extraction methods & analytics like product development. He has been in the cannabinoid industry since 2015.

 

 

Board of Directors

SEBASTIAN STIETZEL​
Chairman of the Board of Directors:

As a serial entrepreneur, his strengths lie in strategy, ops and executive coaching, with particular expertise in post-merger integration and capital market fitness. Sebastian holds a Master's degree in Business Administration with a focus on IT-enabled marketing and human resources.

 

 

 

 

 

 

 

DR. MARLON BRAUMANN
Member of the Board of Directors

Dr. Marlon Braumann is a serial entrepreneur and one of the founding partners of the European VC fund Elevat3 Capital - an investment fund primarily focused on biotech, medtech and fintech investments. In addition, Mr. Braumann is the founder of the global wildlife foundation AMES Foundation

 

 

THOMAS HANKE​
Member of the Board of Directors

Mr. Hanke has extensive transaction experience (private equity, venture capital, growth capital & PIPE transactions) and has held various interim operational mandates in portfolio management in addition to his investor activities.

 

SynBiotic SE - Anayst Presentation (May 2021): Download

Publications

  • Ad-hoc-Releases
  • Corporate News
  • Financial Reports
  • Other Documents

 

01. December 2020: Securities Prospectus



Annual General Meetings

  • 2020
  • 2021
  • Financial Dates

 

The Annual General Meeting will be held in July 2021. The exact date and time will be announced.

 

  • June 2021 | Publication of the annual financial statements as of 31.12.2020
  • July 2021 | Annual General Meeting
  • September 2021 | Publication of the half-year report
  • 24. September 2021 | Baader Investment Conference

Contact

If you have any further questions, please do not hesitate to contact us. You can reach us by e-mail or directly on the phone. In addition, we will be happy to include you in our IR news service. This way, you will directly receive all information on investor relations topics of SynBiotic SE. For voting rights notifications to the company, please use the contact details below.

ADDRESS

SynBiotic SE
Barer Str. 7 
80333 München

CONTACT PERSON

Johannes Fontner, M.A.
Finance & Investor Relations
Tel.: +49 7522 2674910
Mail: jf@synbiotic.com

E-MAIL

jf@synbiotic.com